Randomized phase III study of gemcitabine, cisplatin plus S ‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

ConclusionsGCS is the first regimen which demonstrated survival benefits as well as higher RR over GC in a randomized phase III trial and could be the new first-line standard chemotherapy for advanced BTC. To exploit the advantage of its high RR, GCS is now tested in the neoadjuvant setting in a randomized phase III trial for potentially resectable BTC.

Source: Journal of Hepato-Biliary-Pancreatic Sciences - August 9, 2022 Category: Gastroenterology Authors: Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Tags: ORIGINAL ARTICLE Source Type: research